Global Antiplatelet Drugs Market Size was valued at US$ 1.5 Billion in 2017 and is Expected to Witness a CAGR of 7.6% Over the Forecast Period (2018 – 2026)

Antiplatelet Drugs

Individuals with a history of heart attacks are administered antiplatelet medicines, which help to prevent heart attacks from happening again. Aspirin, clopidogrel, prasugrel, and ticagrelor are examples of antiplatelet medicines. In the absence of hypersensitivity, aspirin is indicated for all individuals with Acute Coronary Syndrome (ACS). It's usually taken with one of the antiplatelet drugs like Clopidogrel, Prasugrel, or Ticagrelor. Prasugrel is given to individuals with ACS and those who are having a Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor are used to prevent atherothrombotic events in adult patients with ACS who have had a coronary artery bypass graft (CABG) or PCI.

The Antiplatelet Drugs Market is predicted to develop as the frequency of cardiovascular disorders rises. The global antiplatelet medicines market is being driven by an increase in the prevalence of cardiovascular illnesses, a growing elderly population, and a sedentary lifestyle. In both developed and developing economies, cardiovascular illnesses are the leading cause of death. According to the Centers for Disease Control and Prevention (CDC), over 800,000 individuals in the United States die each year from stroke and other cardiovascular disorders, according to data from 2015. Rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease are some of the most common cardiovascular illnesses.

Market Restraints for Antiplatelet Drugs

Some Antiplatelet Drugs Market, however, have limits in terms of efficacy, safety, and tolerability, preventing their usage in patients. Antiplatelet medicines, for example, might irritate the stomach lining, resulting in gastrointestinal side effects such as indigestion and stomach aches. Furthermore, because these medications lower the ability of the blood to clot, people taking them may be more prone to nosebleeds, bruising, or bleeding for longer periods of time than usual. 

According to a 2011 article published in the Journal of Clinical Gastroenterology, the gastrointestinal system is the site of most spontaneous bleeding in patients using antiplatelet medicines, with an incidence of 2-3 percent with dual antiplatelet therapy. Furthermore, due to rebound platelet activation, failing to take antiplatelet medicines as prescribed can raise the risk of thrombotic problems. During the projected period, all of these factors are expected to limit the growth of the Antiplatelet Drugs Market.